LLY

1,124.13

+3.88%↑

JNJ

230.35

-0.62%↓

ABBV

218.59

+1.72%↑

UNH

383.33

+0.29%↑

MRK

119.53

-1.04%↓

LLY

1,124.13

+3.88%↑

JNJ

230.35

-0.62%↓

ABBV

218.59

+1.72%↑

UNH

383.33

+0.29%↑

MRK

119.53

-1.04%↓

LLY

1,124.13

+3.88%↑

JNJ

230.35

-0.62%↓

ABBV

218.59

+1.72%↑

UNH

383.33

+0.29%↑

MRK

119.53

-1.04%↓

LLY

1,124.13

+3.88%↑

JNJ

230.35

-0.62%↓

ABBV

218.59

+1.72%↑

UNH

383.33

+0.29%↑

MRK

119.53

-1.04%↓

LLY

1,124.13

+3.88%↑

JNJ

230.35

-0.62%↓

ABBV

218.59

+1.72%↑

UNH

383.33

+0.29%↑

MRK

119.53

-1.04%↓

Home・Stock List・MannKind Corp

MannKind Corp

Open

SectorHealthcare

3.57 0.85

Buy Sell

Overview

Share price change

24h

Current

Min

3.46

Max

3.67

Key metrics
By Trading Economics
Income	-671K -17M
Sales	-22M 90M
P/E Sector Avg	140.5 50.102
EPS	-0.02
Profit margin	-18.431
Employees	591
EBITDA	5.9M 3.4M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+116.15% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	177M 1B
Previous open	2.72
Previous close	3.57

News Sentiment

By Acuity

37%

63%

79 / 344 Healthcare

MannKind Corp Chart

Past performance is not a reliable indicator of future results.

Related News

27 May 2026, 21:33 UTC

Earnings

Correction to Salesforce 1Q Sales, Profit Rise Article

27 May 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 May 2026, 20:18 UTC

Earnings

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 May 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 May 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 May 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 May 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 May 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 May 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 May 2026, 21:29 UTC

Hot Stocks

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 May 2026, 21:08 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 May 2026, 21:02 UTC

Earnings

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 May 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 May 2026, 20:55 UTC

Earnings

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 May 2026, 20:48 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 May 2026, 20:45 UTC

Earnings

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 May 2026, 20:34 UTC

Acquisitions, Mergers, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 May 2026, 20:32 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 May 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 May 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 May 2026, 20:30 UTC

Earnings

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 May 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 May 2026, 20:22 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 May 2026, 20:16 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 May 2026, 20:13 UTC

Earnings

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 May 2026, 20:13 UTC

Earnings

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 May 2026, 20:13 UTC

Earnings

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 May 2026, 20:12 UTC

Earnings

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 May 2026, 20:12 UTC

Earnings

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

116.15% upside

12 Months Forecast

Average 7.63 USD 116.15%

High 10 USD

Low 4.75 USD

Based on 6 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Sentiment

By Acuity

79 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.